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Abstract 
Prior to the first successful bone marrow transplant in 1968, patients born with severe 
combined immunodeficiency (SCID) invariably died. Today, with a widening availability 
of new born screening, major improvements in the application of allogeneic procedures, 
and the emergence of successful haematopoietic stem and progenitor cell (HSC/P) gene 
therapy, the majority of these children can be identified and cured. Here we trace key 
steps in the development of clinical gene therapy for SCID and other primary 
immunodeficiencies (PIDs), and review the prospects for adoption of new targets and 
technologies. 
 
Primary Immunodeficiencies as targets for gene therapy 
Primary immunodeficiencies (PID) are a diverse group of rare largely monogenic 
disorders that result in variable susceptibility to infection, autoimmunity/inflammation, 
and in some cases malignancy. Over 300 genes have now been associated with syndromic 
and non-syndromic PID, including the most frequently occurring forms[1]. The severest 
PIDs present early in life with failure to thrive and severe infections (often 
opportunistic), and are usually fatal unless definitive therapy can be implemented 
rapidly[2]. Fortunately many of these immunological defects are intrinsic to the 
haematopoietic system making them tractable targets for allogeneic haematopoietic stem 
cell transplantation (HSCT). Since the first successful bone marrow transplants in two 
PIDs, X-linked SCID (SCID-X1) and Wiskott Aldrich Syndrome (WAS), HSCT 
methodologies and technologies (including conditioning regimens) have improved and 
the morbidity and mortality associated with this procedure have diminished 
considerably[3-6]. Even so, for patients without HLA-matched donors, graft-versus-host 
disease (GvHD), delayed immunological reconstitution, and graft rejection remain a 
significant problem. Some conditions are better candidates than others due to disease-
specific characteristics, and risks are heightened in patients who are actively infected or 
who have developed chronic complications at the time of treatment. More than thirty 
years ago the demonstration of retroviral gene transfer to HSC/Ps led to the suggestion 
that this technology could provide an alternative platform for development of therapies 
in a number of diseases that were amenable to HSCT[7-11]. The advantages of 
autologous gene therapy were anticipated to lie in the lack of need to identify a suitable 
donor, obviation of GvHD, and the potential to reduce the risks of myelosuppressive 
and immunosuppressive pre-conditioning of the patient, which is required to make space 
for engrafting HSC/Ps. For some conditions it was expected that corrected cells would 
have a profound growth and survival advantage, allowing reconstitution from relatively 
low numbers of cells. In addition, expression of transgenes at supraphysiological levels 
was anticipated to allow “cross correction” of other deficient non-haematopoietic cells in 
some diseases[12].  Over a number of years, successful correction of cellular and animal 
models boosted expectation that gene therapy would rapidly become mainstream, but 
clinical translation proved more difficult (Figure 1). This partly related to a limited 
understanding of human HSC/P culture conditions necessary to achieve high-level gene 
transfer ex vivo yet at the same time retaining in vivo engraftment capability, which was not 
well modelled in murine preclinical transplant assays[13].  Furthermore, the occurrence 
of clinically-manifesting insertional mutagenesis highlighted deficiencies in early retroviral 
vector technology that would have to be resolved[14]. 
 
Adenosine-deaminase-deficient (ADA)-SCID as a paradigm for development of 
HSC gene therapy 
Adenosine deaminase (ADA) is a housekeeping enzyme of the purine metabolic 
pathway, and is widely expressed[15]. The metabolic environment resulting from 
deficiency of ADA and the accumulation of toxic purine metabolites causes variable 
skeletal, lung, liver, gastrointestinal, neurodevelopment and sensorineural defects, 
whereas the most consistent and profound abnormality is in the development of 
lymphocytes, including T, B and natural killer cells[16, 17].  Exogenous polyethylene 
glycol-conjugated ADA (PEG-ADA) can rescue the immunological defects through 
extracellular detoxification, but these effects are often partial and poorly sustained[18].  
Even so, the use of PEG-ADA at diagnosis has proved a very useful way to stabilise 
patients before a definitive procedure can be implemented[19, 20].  Several clinical trials 
were implemented in the early 1990’s using gammaretroviral vectors that had been 
evaluated in murine and primate model systems, and in which ADA cDNA transgene 
expression was regulated by the retroviral Long-Terminal-Repeat (LTR). It was also 
anticipated that the selective growth and survival advantage imparted to gene-corrected 
cells would obviate the need for pre-conditioning of the patient. However, these early 
studies using residual peripheral blood lymphocytes, umbilical cord blood, and bone 
marrow failed to provide clear clinical benefit over and above that of PEG-ADA, which 
the patients continued to receive[21-24].  Subsequent studies (again using LTR-intact 
gammaretroviral vectors) introduced some key changes, including the withdrawal of 
PEG-ADA to enhance the selective advantage of corrected cells, and most importantly 
the use of low/reduced intensity conditioning with alkylating agents (usually busulphan, 
in a few patients melphalan) to promote engraftment of HSC/Ps[25-32].  The combined 
overall survival of around 50 patients treated in these studies was 100%, with a disease-
free survival (not requiring re-introduction of PEG-ADA or HSCT) of over 70%. 
Immunological reconstitution has in general been robust, with high-level gene marking in 
lymphocytes, and for the first time, sustained gene marking albeit at lower levels in 
myeloid cells, which is an effective surrogate for HSC/P marking in bone marrow. 
Permanent withdrawal of immunoglobulin supplementation was achieved in 
approximately 50% of patients, suggesting that further improvements are still possible. 
Recently, a collaboration between GSK, Fondazione Telethon and Ospedale San 
Raffaele secured European Marketing Authorisation for StrimvelisTM which is based on 
the original LTR-based vector studied in Milan[22].  From proof of concept in humans 
to this first ex-vivo market authorisation for a gene therapy product, vector technology 
has advanced considerably. HIV-1 based lentiviruses in particular have been adopted as 
the current vector of choice for HSC/P gene transfer as they appear to offer some 
advantages in terms of mutagenicity (because of a more favourable genome insertion 
profile within transcriptional units rather than at transcription start sites (TSS), a 
theoretical advantage) lack of intrinsic retroviral LTR enhancer activity (a modification 
that has also been duplicated in a new generation of gamma retroviruses), and higher 
efficiency of gene transfer[33-35].  Following several years of preclinical development, 
clinical studies using lentiviral vectors are underway for ADA-SCID[36]. Early 
indications in over 32 treated patients, some of whom were identified by newborn 
screening, are of excellent efficacy, and no associated toxicity[37].  
 
Interestingly, no clinically-manifesting vector-related toxicities have been observed in any 
of these studies to date. This is surprising because vectors with similar configurations 
have caused mutagenesis and malignancy in a number of other conditions as will be 
highlighted later[38, 39].  Several reports have now detailed a comprehensive analysis of 
retroviral integration sites (RIS) in cells from ADA-SCID patients treated with LTR-
intact gammaretroviral vectors, and although the anticipated patterns of integration are 
observed, namely preference for transcriptional start sites (TSS), including sites near the 
proto-oncogenes Lim domain only 2 (LMO2), BCL2 and CCND2, there are also 
indications of subtle mutagenic clonal disturbances, although apparently insufficient to 
drive a frank malignant programme[37, 40, 41]. The reason for this disease-specific 
difference in toxicity is at present unclear, but could relate to a lower replicative stress in 
reconstituting T cells on the non-haematopoietic environmental background of ADA-
deficiency in the thymus, or the presence of competing non-transduced but detoxified 
thymocytes that successfully complete their maturation programme [42]. However, this 
still doesn’t explain the lack of myeloid toxicity unless a similar argument can be applied 
to the bone marrow microenvironment or even during ex vivo culture. 
 
Lessons learned from clinical trials in X-linked SCID (SCID-X1)  
X-linked SCID (for SCID-X1) is the most common form of severe combined 
immunodeficiency, accounting for 40-50% of all cases[2].  Mutations in the IL2RG gene 
lead to defective expression of the common cytokine receptor gamma chain (gc), so-
called because it is subunit shared by multiple cytokine receptors, including the IL-2, IL-
4, IL-7, IL-9, IL-15 and IL-21 receptor complexes, which are variably involved in the 
development and function of all lymphocytes. As a consequence, patients show 
profound defects of adaptive immunity, resulting from the low number or absence of T 
and Natural Killer (NK) lymphocytes, and the loss of function of B lymphocytes. The 
first two clinical trials of gene therapy for SCID-X1 included a total number of 20 
subjects and were conducted using virtually identical LTR-intact gammaretroviral vectors 
and very similar transduction protocols[43-46]. Neither study used preconditioning, with 
the expectation that the extremely high survival advantage of corrected lymphocyte 
precursors would allow the development of a highly diverse T cell repertoire (as 
observed following HLA-matched HSCT infusions, and in some variant patients with 
rare somatic reversion events) [47, 48].  Successful recovery of a functional T cell 
compartment occurred in most patients and has been sustained with a disease free 
survival over 80%, and excellent overall clinical outcome. In the absence of conditioning, 
sustained engraftment of HSCs did not occur, and consequently long-term B cell and 
NK cell marking was very low. Unfortunately 31-68 months after gene therapy, five 
patients who were clinically well and had successfully reconstituted, developed a T-cell 
acute lymphoblastic leukaemia (T-ALL)[49-51].  In four out of five patients enhancer-
mediated upregulation of the LMO-2 protooncogene was directly implicated in the 
leukaemic process, although an accumulation of more classical genetic changes (many of 
which have been previously described in de novo T-ALL) unrelated directly to retroviral 
vector insertion, were probably required for final evolution to acute T-ALL[51, 52].  It 
has recently been postulated that intra-thymic replicative stress in the absence of T cell 
progenitor import from the bone marrow is a significant contributor to the establishment 
of a leukaemic programme  as HSC engraftment is essentially absent[42, 53]. If this is the 
case, then use of conditioning would likely reduce risk of clinically manifesting 
mutagenesis. No convincing evidence could be confirmed for a pathogenic role of non-
physiological expression of the transgene in leukaemogenesis through aberrant receptor 
signalling, although of course it allowed the T cell maturation to proceed[54]. All patients 
were treated with relatively standard chemotherapy, but one patient died of refractory 
leukaemia. Remarkably, the four surviving patients recovered their T cell immunity after 
completion of chemotherapy without need for any further intervention. This suggests 
that a very long lasting (possibly self-renewing), gene-corrected T cell precursors 
engrafted in the thymus soon after infusion of cells, and that these are capable of 
sustaining active thymopoiesis for many years.  
 
Molecular studies in mice engrafted with cells transduced with replication-incompetant 
gammaretroviral vectors identified duplicated enhancer elements in the LTR as the major 
culprit driving dysregulated gene expression in the neighbourhood of the RIS[38, 55, 56]. 
This effect was also shown to have activity over quite long ranges, and to operate 
combinatorially with other molecular lesions[51, 52]. As part of an international 
collaboration, the Transatlantic Gene Therapy Consortium (TAGTC), a new generation 
of gammaretroviral technology was developed that deleted the LTR enhancer sequences, 
and used internal heterologous sequences to regulate transgene expression[57-59].   
Assays were developed that demonstrated significantly reduced mutagenicity in vitro, 
while testing in animal models of disease, including SCID-X1 suggested that these new 
vectors designed for safety also retained efficacy[55, 60-62]. In a recently reported clinical 
study, 9 newly diagnosed patients with SCID-X1 were treated with a modified 
gammaretroviral vector using a very similar protocol to that previous implemented, and 
with similar outcomes in terms of immunological reconstitution[63]. More importantly, 
when RIS were compared to those retrieved from trials using LTR-intact 
gammaretroviruses, there was significantly less clustering within the LMO-2 or MECOM 
loci, or at other proto-oncogenes implicated in leukaemogenesis. No vector-related 
adverse events have been observed to date, with a median follow up of over 5 years. 
Interestingly, the rate of early T cell reconstitution following autologous gene therapy has 
also been shown to be faster than that following haploidentical HSCT suggesting that 
there are other advantages of this approach[64]. 
 
As part of the first two studies, two older patients were also treated but did not 
reconstitute[65]. Similarly, in a third trial (with an LTR-intact gammaretroviral vector) 
using peripheral blood mobilised HSC/P cells rather than bone marrow-derived cells, 
two preadolescent subjects aged 10 to 14 years, who had previously been treated 
unsuccessfully with bone marrow transplantation, received transduced cells in the 
absence of conditioning[66]. Immune reconstitution was limited in these patients despite 
good engraftment, with only a slight improvement of T cell function in the youngest 
child. It has been proposed that there is an age-related decrease in plasticity and loss of 
thymopoietic capacity in older subjects particularly where thymopoiesis has been absent 
for extended periods. More recently a lentiviral vector approach has been used to treat 5 
patients who have failed haploidentical HSCT, in a protocol that included reduced 
intensity conditioning with busulphan[67]. All 5 patients demonstrated expansion of gene 
marked T, B and NK cells, with clinical benefit. Interestingly these patients responded to 
therapy well despite their older age, and achieved successful recovery of humoral 
function. This suggests that the engraftment of corrected HSC, facilitated by the 
lentiviral vector platform and pre-conditioning, allows superior recovery to that observed 
in gammaretroviral studies. Studies are currently ongoing in newly diagnosed infants. 
 
All clinical approaches so far have utilised ex vivo manipulation of HSC/P cells, which 
although advantageous for product quality testing, does add some complexity in terms of 
manufacture. In an alternative approach, a clinically relevant canine model of SCID-X1 
has been used to demonstrate partial correction through direct inject of a foamy virus 
vector in neonatal animals (again relying on selective growth and survival advantage of 
corrected cells)[68]. Whether this can be translated into a clinical protocol for newly 
diagnosed SCID patients or even for in utero application is unknown, but the efficiency of 
ex vivo gene therapy may be difficult to challenge. 
 
Gene therapy for Chronic Granulomatous Disease: no selective advantage 
Chronic Granulomatous Disease (CGD) results from deficiency of the multicomponent 
NADPH-oxidase enzyme complex in professional phagocytic cells[69, 70]. This oxidase 
is directly responsible for mitochondria-independent consumption of oxygen during 
phagocytosis (called the respiratory burst), which results in forced electron transport 
across the phagosome membrane, production of reactive oxygen species such as 
superoxide anion radical, hydrogen peroxide, hydroxylanion and hypochlorous acid 
(although the functional significance of these species in vivo is uncertain), liberation and 
activation of crucial microbicidal granule proteases through change in local pH and ionic 
balance, and effective formation of extracellular neutrophil nets[71, 72]. Patients with 
CGD are consequently susceptible to recurrent life-threatening infections by a spectrum 
of bacteria and fungi, particularly those which express high levels of catalase (so-called 
‘catalase-positive organisms’ such as Staphylococcus Aureus, Nocardia and Aspergillus. In two 
thirds of cases, CGD is due to mutations in the X-linked CYBB gene (X-CGD), which 
encodes the gp91phox component of the NADPH-oxidase complex, although a significant 
proportion have mutations in NCF1 which encodes p47phox (AR-CGD). Three other AR 
forms of CGD have been described, and while rare in Western populations, are much 
more prevalent in geographical areas of high consanguinity. The level of correction 
absolutely required for clinical benefit in CGD is unknown. However female carriers of 
X-CGD with over 10% of circulating functional neutrophils are usually well. The level of 
biochemical activity necessary per cell is also an important question, although patients 
with very low levels of natural activity have a significant survival advantage over those 
with no detectable activity, and animal studies predict that partial correction will be 
sufficient[73, 74]. One of the complexities of treating CGD through an HSC approach is 
that there is no selective advantage for corrected cells. Furthermore, chronic 
inflammation may have a detrimental effect on HSC/P numbers and viability after ex-vivo 
manipulation[75, 76].  Early trials did not use any preconditioning of patients, and 
engraftment was therefore at very low level and transient[77]. More recently, five early 
phase clinical studies, involving a total of 12 patients have been conducted in several 
centres worldwide, incorporating reduced intensity alkylating agent conditioning[75, 78-
80]. Overall, these demonstrated biologically and clinically significant restoration of 
NADPH-oxidase activity (albeit partial, between 10-30% of normal) in circulating 
neutrophils for a short time after engraftment, allowing the majority of patients to clear 
pre-existing infections. However, clinical benefit was usually only transient, and gene 
marking rapidly decreased with only a few patients having significant marking after three 
months. Several patients treated with a Spleen Focus Forming Virus (SFFV)-derived 
LTR-based gammaretroviral vector developed an unexpected increase in the number of 
functionally corrected neutrophils over time as a result of insertional transactivation of 
myeloproliferative genes, particularly PRDM16 and the MECOM locus[78, 81]. 
Interestingly, although the level of gene marking persisted, gene expression was silenced 
in the majority of these cells through CpG dinucleotide methylation at the retroviral 
promoter, even though enhancer activity and therefore mutagenic influence was 
preserved.  
 
More recently, lentiviral gene therapy approaches for CGD have been developed in an 
attempt to reduce the risk of mutagenesis and enhance long-term efficacy. In the first 
approach a chimeric promoter (fusion between c-fes and Cathepsin G proximal 
regulatory sequences) was developed that contains binding sites for transcription factors 
that are active during terminal myeloid differentiation[82]. Consequently it confers higher 
levels of gene expression in differentiated myeloid cells rather than in non-myeloid 
lineages or multipotent primitive progenitors where mutageneic influences are least 
desirable. HSC gene therapy using this vector in mice resulted in high levels of gp91phox 
expression in committed myeloid progenitors and granulocytes with much less 
expression in other lineages, mimicking physiological patterns to a large degree. In 
accordance with these findings, high levels of NADPH oxidase activity was restored in 
all the transplanted animals and remained constant for the period of analysis. Secondary 
transplantation experiments also indicated that the chimeric regulatory sequences were 
not prone to silencing or indeed to epigenetic CpG methylation. A clinical trial is 
currently ongoing in US and Europe using myeloablative busulphan preconditioning, 
with encouraging early results, and evidence for the first time of sustained biochemical 
correction in the absence of mutagenesis[83].  A parallel strategy for AR-CGD has also 
recently been developed. A second approach has been to use vector-encoded micro-
RNA recognition sequences to de-target gene expression away from HSC and therefore 
prevent any potential toxicity arising from transgene expression in these cells[84]. 
 
Gene therapy for Wiskott-Aldrich syndrome (WAS): complex multilineage disease 
Wiskott-Aldrich syndrome (WAS) is a rare, X-linked, complex PID caused by mutations 
in the WAS gene[85, 86]. The Wiskott-Aldrich protein (WASp) is a major regulator of 
the actin cytoskeleton in most haematopoietic lineages and is consequently important for 
normal function of many immunological processes, and for normal platelet 
production[87]. Clinical manifestations of WAS include microthrombocytopenia, 
recurrent infections and eczema. Patients also display an increased incidence of 
autoimmunity and are at risk of developing lymphoreticular malignancy. In a study of 10 
patients treated with an LTR-intact gammaretroviral vector and reduced intensity 
busulphan conditioning, 9 exhibited sustained improvement of immunological function 
with resolution of immunodeficiency and bleeding diatheses[88]. However, despite initial 
evidence for polyclonal RIS patterns, most patients subsequently developed leukaemia as 
a result of insertions at LMO-2 and MECOM loci[89]. This high frequency of leukaemia 
most likely occurred as a combinatorial result of the LTR enhancer activity and multiple 
vector insertions per cell, but also highlights the difficulty in using RIS analysis for 
prediction of dangerous clonal events. More recently, a lentiviral vector incorporating 
proximal WAS regulatory sequences has been tested in several centres, using a reduced 
intensity pre-conditioning regimen[90-93]. In over 20 patients treated worldwide there 
has been sustained correction of immunological parameters in most, with resolution of 
immunodeficiency and autoimmunity, and no evidence to date for mutagenesis. 
Recovery of platelet numbers has been more variable but surprisingly slow in most cases 
and dependent on higher vector copy numbers. One of the benefits of RIS analysis is the 
ability to track physiological haematopoiesis at a clonal level. Using treated WAS patients 
it was therefore possible to define cellular contributions to early and late phases of 
reconstitution, and to show that HSC/Ps manipulated in vitro for gene transfer retained 
the ability to restore haematopoiesis in vivo in a way that mirrors normal HSC activity 
after transplantation[94].  
  
Preclinical development of gene therapy for other candidate PIDs 
The success of gene therapy for several PIDs using conventional gene addition, and the 
apparent improvement in safety through development of newer vector platforms 
suggests that similar strategies could be applied to other PIDs. Autosomal recessive 
Janus Kinase (JAK)-3 deficiency leads to a phenotype that is identical to SCID-X1 
because JAK3 is a tyrosine kinase required for signal transduction by the common 
cytokine receptor gamma chain (deficient in SCID-X1)[95].  Similarly, Interleukin-7 
receptor alpha deficiency results in the same T cell phenotype, with normal numbers of 
B and NK cells. Other tractable forms of SCID include defects in RAG (recombination 
activating genes) 1 and 2 genes, and in DCLRE1C wich encodes Artemis. RAG1/2 and 
Artemis proteins participate in V(D)J  recombination, which is essential for the 
generation of functional B and T cell receptors and consequently for normal T and B cell 
development. In all cases, the transfer of genetically modified HSCs can effectively 
reconstitute murine models of the disease although with varying degree of difficulty[96-
99].  X-linked Agammaglobulinemia (XLA) is caused by mutations in the Bruton’s 
tyrosine kinase (BTK) gene, an enzyme of the TEC family of kinases expressed during B 
cell development and involved in pro-B/pre-B cell transition. The absence of BTK 
results in an accumulation of pro-B cells and a decrease in numbers of mature B cells and 
very low or absent serum immunoglobulins. Preclinical murine reconstitution 
experiments using both gammaretroviral and lentiviral-based gene transfer have 
demonstrated successful rescue of B cell differentiation and function[100, 101].  Similar 
results have been obtained using a more refined lentiviral vector encoding the 
immunoglobulin enhancer (Emu) and Igbeta (B29) minimal promoter to regulate lineage-
specific Btk expression, again in mice[102]. As many XLA-associated mutations affect 
pre-mRNA splicing, attempts have also been made to model correction in a BAC-
transgenic mouse model using splice-correcting oligonucleotides with some success[103]. 
X-linked hyper IgM syndrome (X-HIGM1) is a combined immunodeficiency 
characterised by defects in isotype switching from IgM to IgG, IgA and IgE, as well as 
impaired lymphocyte and myeloid functions. X-HIGM1 is associated with mutations in 
the gene (TNFSF5) encoding CD40 Ligand (CD40L), a member of the TNF 
superfamily, which is primarily expressed on activated T cells, and binds the CD40 
receptor on the surface of B cells and antigen-presenting cells to regulate B cell function 
and inflammatory responses. Gammaretroviral gene transfer has previously been shown 
to successfully correct the phenotype of CD40L-deficient mice, but at the cost of 
pathological T-lymphoproliferation due to phenotoxicity of the expressed gene unrelated 
to insertional mutagenesis[104]. This is consistent with findings from another study, 
which reported atypical lymphoid proliferation in transgenic mice overexpressing 
CD40L, and highlights an important consideration for regulated gene expression in a 
number of these conditions[105]. An alternative strategy to counteract this obstacle by 
corrective trans-splicing was partially effective[106]. X-linked lymphoproliferative disease 
(XLP), a T and NK lymphoproliferative disorder caused by mutations in the signalling 
adaptor SLAM-associated protein (SAP), and familial hemophagocytic 
lymphohistiocytosis (FHLH), a hemophagocytic disease resulting from defective NK and 
CD8+ T cell cytotoxicity are potential candidates for both HSC/P and peripheral T cell-
based approaches[107-109]. SAP is involved in multiple signalling pathways affecting 
proliferation, apoptosis and differentiation, while perforin and Munc13-4, which are the 
most commonly deficient proteins in FHLH, are direct effectors of cytotoxicity. Lineage-
restricted regulation of these genes might be required to avoid deleterious effects in cells 
where these proteins are not normally expressed. Mature T cells may also be viable 
targets as long as sufficient numbers can be engrafted for long-term efficacy, or even for 
bridging to a more definitive HSC procedure. Leukocyte adhesion deficiency (LAD) type 
I, which is caused by mutations in the gene (ITGB2) encoding the CD18 integrin subunit, 
is primarily a neutrophil disorder characterized by recurrent life-threatening bacterial 
infections and poor wound healing. Experience from allogeneic transplant indicates that 
quite low numbers of normal donor neutrophils are sufficient to achieve disease control. 
A preliminary study, in which two patients were treated with gammaretroviral gene 
therapy in the absence of conditioning, achieved very low (<0.1%) levels of gene 
marking in neutrophils, with no corrected cells detectable in the periphery after two 
months[110]. More recently, the canine (CLAD) and murine models of disease have been 
successfully treated using HSCs transduced with either foamy or lentiviral vectors 
expressing CD18[111, 112]. In many of these conditions, preclinical efficacy and safety 
studies using improved viral vectors, including vector platforms developed from other 
classes of retrovirus such as foamy and avian viruses (which may have enhanced safety in 
terms of genetoxicity), are currently being undertaken in order to determine clinical 
applicability[113-115].  
 
Gene editing approaches for PID  
There has been an explosion of gene editing technologies over recent years, including 
homology repair platforms based on zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs), and more recently clustered regularly 
interspaced short palindromic repeats [CRISPR]/CRISPR-associated endonuclease [Cas]-
9]. The advantages over gene addition include safety through precise editing of mutations 
(as long as off-target effects are minimal), targeting specific gene loci to harness natural 
regulatory elements, or targeting to ‘safe harbours’ within the genome, which are known 
to tolerate transgene integration without risk of mutagenesis. Considerable interest has 
been placed on editing in PID, particular where selective advantage is imparted to 
corrected cells (for example in SCID and WAS), or where precise gene regulation is 
desirable (XHIGM, XLA, RAG-SCID, JAK-3-deficient SCID, IL7R-deficient SCID). 
Proof of concept has now been demonstrated in HSC/Ps from SCID-X1 and CGD 
patients (at safe harbour and at natural gene locus), and for XHIGM in T cells[116-118]. 
One intriguing recent report has used a gene editing strategy to convert a mutant NCF1 
pseudogene into a functional gene thereby permitting correction of all molecular variants 
of p47phox-deficient CGD through a single approach[119]. Although functional 
correction through editing has now been demonstrated in iPSCs and human HSC/Ps, it 
still probably remains limited by efficiency in true HSCs, which is required for sustained 
clinical effect in many PIDs[120]. In contrast efficiency of editing in mature T cells can 
be quite high as demonstrated for XHIGM, although the challenge here will be to 
engraft sufficient numbers of T cells for long term effect. These strategies are exciting 
but some careful technology development is required before clinically applicable. Aside 
from obvious concerns about off-target DNA cleavage and illicit recombination, a much 
more pragmatic question exists regarding efficiency and ability to modify sufficient cells 
for clinical benefit. Even for conditions with selective advantages, the dose of cells 
required for immunological recovery is high as determined by clinical experience with 
gene addition and allogeneic HSCT. Where homologous recombination is required for 
effect this will be challenging. However, for dominant disorders where gene disruption is 
the desired effect (for example gain of function STAT1/STAT3-related disease), this 
strategy may be more immediately tractable, although specificity of editing of the variant 
allele would have to be carefully titrated, and depending on the disease, virtually all cells 
will have to be modified in order to prevent residual pathology. 
 
Reflections 
PIDs have played a significant part in the development of allogeneic HSC 
transplantation, and more recently have shown that somatic gene therapy is a viable and 
effective approach in patients. They undoubtedly will also feature prominently in the 
application of gene editing to human disease. Over 150 patients with various forms of 
PID have been treated worldwide by autologous gene therapy to date. More recent 
studies with refined vector technologies have demonstrated excellent safety profiles, and 
compelling evidence for clinical benefit in several diseases (Figure 2). Many challenges 
need to be overcome before gene therapy can be offered as a standard of care for all 
patients, although the recent market authorisation for StrimvelisTM indicates the direction 
of travel. There is now a steady increase in capitalization of gene therapy approaches in 
start-up biotechnology firms and some established pharmaceutical companies, reflecting 
a renewed appetite for commercialisation of therapies for these rare diseases. Future 
challenges lie in the design of safer vectors, in the incorporation of regulatory elements 
to achieve clinical efficacy, effective methodologies for gene editing, and in the 
optimisation of cell culture methods to preserve viability and function during 
manufacture of products. Application of pluripotent stem cells derived from somatic 
tissues by reprogramming (induced pluripotent stem (iPS) cells) may aid in gene editing 
applications if safe and effective means of successfully transplanting in vitro derived 
tissues can be developed. Somewhat surprisingly, a current bottleneck is the lack of 
capacity for clinical grade production of viral vectors, which is contributed to by the 
difficulties in massive scale-up of the lentivirus platform required for treatment of large 
numbers of patients. Logistics of delivery of cryopreserved cell products to the patient 
from a limited number of manufacturing centres will also need to be addressed. In the 
absence of in-vivo selection methodologies, for most PIDs there is a requirement for pre-
conditioning. Less toxic strategies for example using serotherapy to deplete HSCs is one 
attractive option. At the same time that allogeneic HSCT has become much more 
sophisticated and flexible through use of alternative stem cell sources, which significantly 
attenuate the need for extended searches for donors, and more refined conditioning 
regimens, autologous gene therapy for PID has begun to deliver impressive returns in 
terms of efficacy and safety in patients. Alongside newborn screening for SCID, the 
outlook for patients diagnosed with severe PID is looking very good.  
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Figure Legends 
Figure 1. The development of viral vector technology and its application to human gene 
therapy. The blue time line shows the various ups and downs of the field based on 
successes and setbacks. References are included in the text. 
 
Figure 2. A table of published and ongoing clinical trials for primary immune 
deficiencies. The disease, mutated gene, vector platform, use of conditioning and year are 
included.  
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